TrialNet is dedicated to testing new approaches to the prevention and early intervention for type 1 diabetes (T1D). With a network 160,000+ diabetes patients and family members worldwide, the goal of TrialNet is to enhance the understanding of demographic, immunologic and metabolic characteristics of individuals at risk for development type 1 diabetes.
TrialNet is an international network dedicated to the study, prevention, and early treatment of type 1 diabetes. TrialNet sites are located throughout the United States, Canada, Finland, United Kingdom, Italy, Germany, Sweden, Australia and New Zealand. Its mission is to use the knowledge gained through clinical research to prevent T1D and stop disease progression by preserving insulin production before and after diagnosis.
The network was established in response to the Surgeon General’s Report Healthy People 2000. This report identified diabetes as a national health objective for the United States. In response, congress created the Diabetes Research Working Group (DRWG) to develop a plan of action for diabetes research. One of their recommendations was to conduct additional research studies toward preventing type 1 diabetes.
Consequently, the Diabetes Prevention Trial of Type 1 (DPT-1) was launched in 1994. DPT-1 was a large multicenter, randomized, controlled clinical trial to investigate the possibility of delaying or even preventing clinical onset of T1 with daily doses of insulin in individuals at risk for the disease. When the trial concluded, TrialNet was created to continue this important work and find a way to prevent T1D.
Whether T1D family, a TrialNet participant, healthcare provider or a clinical researcher visit the website to learn more about the network.